Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Hawkeye 360 Represents 'Compelling' Opportunity With Organic Growth, Margin Expansion, RBC Says

Hawkeye 360 Represents 'Compelling' Opportunity With Organic Growth, Margin Expansion, RBC Says

MT newswireMT newswire2026/09/30 15:10
11:10 AM EDT, 09/30/2026 (MT Newswires) -- Hawkeye 360 (HAWK) represents a "compelling" investment opportunity with an organic growth outlook of around 30% and margin expansion, RBC Capital Markets said in a Wednesday note. The company benefits from a robust recurring revenue model as the leading supplier of commercial signals intelligence data and analysis to the US government, RBC analysts said. They expect margin and free cash flow improvement as Hawkeye benefits from new satellite technology and strong demand. Hawkeye's international exposure is a positive compared with its peers, with sales providing better pricing and longer contracts. US sales should be boosted by increased platform opportunities, and customer expansion through the National Reconnaissance Office's Commercial Radio Frequency Capability Augmentation program, which was awarded last month, the analysts said. However, the company has been dragged down by the broader de-rating of the defense tech sector, reflecting investor concerns about the spending of the US Department of Defense, the analysts said. RBC maintained the company's stock rating at outperform and lowered the price target to $28 from $33. Price: 15.47, Change: +0.09, Percent Change: +0.59
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results

Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.

智通财经•2026/10/13 01:56

Kroger (KR.US) faces the largest layoffs in 143 years: cutting one-third of positions, more than 3,000 employees to be let go

Kroger has laid off 3,000 employees, accounting for more than one-third of its total workforce, marking the largest layoff in its 143-year history. The resources saved will be redirected towards price reductions and frontline operations.

智通财经•2026/10/13 01:36